Literature DB >> 11456132

Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver.

S Kitamura1, K Sugihara, R Hosokawa, Y Akagawa, S Ohta.   

Abstract

Drug-reducing ability of monkey liver cytosol was examined in this study. Monkey liver cytosol exhibited significant reductase activities toward zonisamide, sulindac and imipramine N-oxide in the presence of 2-hydroxypyrimidine or benzaldehyde, an electron donor to aldehyde oxidase. These activities were abolished by inhibitors of aldehyde oxidase, such as menadione. These reductase activities in monkeys were extremely high compared to those in other animals. The zonisamide reductase activity of monkey liver cytosol was about 40-fold higher than that of the liver microsomes. It appears that the high levels of aldehyde oxidase exists in monkey liver, and zonisamide, sulindac and imipramine N-oxide are mainly reduced by this enzyme, not by cytochrome P450.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11456132     DOI: 10.1248/bpb.24.856

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

1.  Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.

Authors:  Jin Won Sung; Hwi-Yeol Yun; Sunny Park; Young Ju Kim; Jeong Yee; Kyung Eun Lee; Byungjeong Song; Jee Eun Chung; Hye Sun Gwak
Journal:  Pharm Res       Date:  2020-01-28       Impact factor: 4.200

2.  Isolation of liver aldehyde oxidase containing fractions from different animals and determination of kinetic parameters for benzaldehyde.

Authors:  R S Kadam; K R Iyer
Journal:  Indian J Pharm Sci       Date:  2008-01       Impact factor: 0.975

Review 3.  Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives.

Authors:  Irfan M Hisamuddin; Vincent W Yang
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533

4.  Construction of expression system of rabbit aldehyde oxidase cDNA for the clarification of species differences.

Authors:  Ping Liu; Sun Liang; Ben-Jie Wang; Rui-Chen Guo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.569

5.  Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers.

Authors:  Yong-Jun Tang; Kai Hu; Wei-Hua Huang; Chong-Zhi Wang; Zhi Liu; Yao Chen; Dong-Sheng Ouyang; Zhi-Rong Tan; Hong-Hao Zhou; Chun-Su Yuan
Journal:  Biomed Res Int       Date:  2017-02-26       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.